INO 4885

Drug Profile

INO 4885

Alternative Names: INO-4885; WW-85

Latest Information Update: 20 Jun 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Inotek Pharmaceuticals
  • Class Metalloporphyrins
  • Mechanism of Action Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Kidney disorders

Highest Development Phases

  • Discontinued Asthma; Kidney disorders; Radiation injuries

Most Recent Events

  • 16 Sep 2010 INO 4885 is available for licensing. www.inotekcorp.com
  • 20 Jun 2008 INO 4885 is still in phase I safety trials for contrast induced nephropathy in USA
  • 09 Oct 2007 Discontinued - Preclinical for Asthma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top